CLLS Stock Analysis: Buy, Sell, or Hold?
CLLS - Cellectis S.A. American Depositary Shares
$2.70
-0.05 (-1.82%)
▼
5d:
-6.57%
30d:
-18.18%
90d:
-31.65%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When CLLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CLLS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CLLS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CLLS is currently trading at $2.70, which is considered oversold relative to its 30-day fair value range of $2.71 to $3.08.
Technical Outlook: Technically, CLLS is in a downtrend. The price is currently testing key support at $2.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.60 (+176.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CLLS is in a downtrend. The price is currently testing key support at $2.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.60 (+176.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.71 -
$3.08
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 176.4% below Wall St target ($7.60)
- CAUTION: Recommendation downgraded due to -6.6% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.71 -
$3.08
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.65
Resistance Level
$2.98
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.09
Wall Street Target
$7.60
(+176.4%)
Revenue Growth (YoY)
-37.3%
Profit Margin
-89.5%
Share & Embed Analysis
Last updated: August 03, 2026 2:25 PM ET
Data refreshes hourly during market hours. Next update: 3:25 PM
Data refreshes hourly during market hours. Next update: 3:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
